• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

戈那瑞林强效激动剂那法瑞林的吸收与代谢

Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone.

作者信息

Chan R L, Henzl M R, LePage M E, LaFargue J, Nerenberg C A, Anik S, Chaplin M D

机构信息

Department of Reproductive Medicine, Syntex Research, Palo Alto, CA 94304.

出版信息

Clin Pharmacol Ther. 1988 Sep;44(3):275-82. doi: 10.1038/clpt.1988.150.

DOI:10.1038/clpt.1988.150
PMID:2970910
Abstract

Nafarelin, a potent gonadotropin-releasing hormone (GnRH) agonist, was absorbed rapidly into systemic circulation (time to reach peak concentration, 20 to 40 minutes) after intranasal but not after sublingual or vaginal administration. Serum elimination half-life was about 2 hours. Nasal absorption of nafarelin was increased by increasing the concentration of the drug in the dose solution and incorporating sodium glycocholate into the nasal formulation. An optimal formulation providing maximum nasal absorption of nafarelin was one containing 1.75 mg nafarelin per ml and 2% sodium glycocholate. Bioavailability of this nasal formulation relative to a single subcutaneous dose averaged 21%. The metabolism and excretion of nafarelin were determined in three subjects after subcutaneous administration of [14C]-nafarelin. Radioactivity was excreted in approximately equal amounts in urine and stool. Six metabolites accounted for most of the radioactivity in urine. Four metabolites were short peptide fragments of nafarelin and the other metabolites were naphthylalanine and 2-naphthylacetic acid.

摘要

那法瑞林是一种强效促性腺激素释放激素(GnRH)激动剂,经鼻内给药后能迅速吸收进入体循环(达峰浓度时间为20至40分钟),但经舌下或阴道给药后则不然。血清消除半衰期约为2小时。通过增加剂量溶液中药物的浓度以及在鼻腔制剂中加入甘氨胆酸钠,那法瑞林的鼻腔吸收得以增强。提供那法瑞林最大鼻腔吸收的最佳制剂是每毫升含1.75毫克那法瑞林和2%甘氨胆酸钠的制剂。该鼻腔制剂相对于单次皮下给药的生物利用度平均为21%。在三名受试者皮下注射[14C] - 那法瑞林后,对那法瑞林的代谢和排泄情况进行了测定。放射性在尿液和粪便中的排泄量大致相等。六种代谢产物占尿液中大部分放射性。四种代谢产物是那法瑞林的短肽片段,其他代谢产物是萘丙氨酸和2 - 萘乙酸。

相似文献

1
Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone.戈那瑞林强效激动剂那法瑞林的吸收与代谢
Clin Pharmacol Ther. 1988 Sep;44(3):275-82. doi: 10.1038/clpt.1988.150.
2
Bioavailability of nafarelin in healthy volunteers.那法瑞林在健康志愿者中的生物利用度。
Am J Obstet Gynecol. 1992 Feb;166(2):762-5. doi: 10.1016/0002-9378(92)91710-r.
3
Nasal absorption of nafarelin acetate, the decapeptide [D-Nal(2)6)]LHRH, in rhesus monkeys. I.
J Pharm Sci. 1984 May;73(5):684-5. doi: 10.1002/jps.2600730523.
4
Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in the rhesus monkey.在恒河猴体内鉴定醋酸那法瑞林(一种促黄体生成激素释放激素的强效激动剂)的主要尿液代谢物。
Drug Metab Dispos. 1985 Sep-Oct;13(5):566-71.
5
Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.与口服达那唑相比,鼻喷那法瑞林治疗子宫内膜异位症的多中心双盲对照临床试验。
N Engl J Med. 1988 Feb 25;318(8):485-9. doi: 10.1056/NEJM198802253180805.
6
Nafarelin acetate: a gonadotropin-releasing hormone agonist for the treatment of endometriosis.
DICP. 1990 Dec;24(12):1204-9. doi: 10.1177/106002809002401212.
7
Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin).
Fertil Steril. 1985 Nov;44(5):583-8.
8
Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).促性腺激素释放激素激动剂类似物(那法瑞林)给药期间垂体-卵巢功能的剂量依赖性抑制
J Clin Endocrinol Metab. 1986 Dec;63(6):1334-41. doi: 10.1210/jcem-63-6-1334.
9
Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.那法瑞林。对其药效学和药代动力学特性以及在性激素相关病症中的临床潜力的综述。
Drugs. 1990 Apr;39(4):523-51. doi: 10.2165/00003495-199039040-00005.
10
Gonadotropin-releasing hormone analogs: update on new findings.促性腺激素释放激素类似物:新发现综述
Am J Obstet Gynecol. 1992 Feb;166(2):757-61. doi: 10.1016/0002-9378(92)91709-j.

引用本文的文献

1
Endocrine Responses to Triptorelin in Healthy Women, Women With Polycystic Ovary Syndrome, and Women With Hypothalamic Amenorrhea.健康女性、多囊卵巢综合征女性和下丘脑性闭经女性对曲普瑞林的内分泌反应。
J Clin Endocrinol Metab. 2023 Jun 16;108(7):1666-1675. doi: 10.1210/clinem/dgad026.
2
Mechanism of transport enhancement of LHRH through porcine epidermis by terpenes and iontophoresis: permeability and lipid extraction studies.萜类化合物和离子导入法促进促黄体生成素释放激素透过猪表皮的转运机制:渗透性和脂质提取研究
Pharm Res. 1998 Dec;15(12):1857-62. doi: 10.1023/a:1011906022903.
3
A risk benefit assessment of drugs used in the treatment of endometriosis.
用于治疗子宫内膜异位症药物的风险效益评估。
Drug Saf. 1994 Aug;11(2):104-13. doi: 10.2165/00002018-199411020-00005.
4
Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.那法瑞林。对其药效学和药代动力学特性以及在性激素相关病症中的临床潜力的综述。
Drugs. 1990 Apr;39(4):523-51. doi: 10.2165/00003495-199039040-00005.
5
Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans.醋酸亮丙瑞林经鼻腔和吸入给药至大鼠和健康人体后的生物利用度。
Pharm Res. 1992 Feb;9(2):244-9. doi: 10.1023/a:1018997625726.
6
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.晚期乳腺癌中使用的内分泌药物的临床药代动力学
Clin Pharmacokinet. 1992 May;22(5):327-58. doi: 10.2165/00003088-199222050-00002.
7
Percutaneous absorption enhancement of leuprolide.
Pharm Res. 1992 Dec;9(12):1575-9. doi: 10.1023/a:1015860324161.